Two friends walking a sunny valley road lined with red lamps tended by lamplighters.
Back to the library

Recovery

Red light and oral mucositis in cancer care

This is the one use where red light is written into mainstream international guidelines. A meta-analysis of eighteen randomised trials in 1,144 people reported that preventive light inside the mouth cut the risk of severe mucositis by around 63 per cent, and the MASCC and ISOO bodies now recommend specific wavelengths and doses for people having stem cell transplant conditioning or head and neck radiotherapy. It is a hospital procedure carried out by trained staff with a small intraoral probe at tightly specified settings. It is included here not because a panel does the same thing, but because it shows the underlying biology is real when the dose is controlled.

Evidence so far
Strong
Reading timeAbout 12 minutes

Start here

Why this is being studied

Oral mucositis is the painful ulceration of the mouth lining that affects most people having high-dose chemotherapy before a stem cell transplant or radiotherapy to the head and neck, and it can be severe enough to stop someone eating or to interrupt their cancer treatment. Red light at 632.8, 650 or 660 nm is applied directly to the lining of the mouth, a tissue only a fraction of a millimetre thick, so the dose delivered is far more predictable than anywhere else in this field. The proposal is that light absorbed by mitochondria in those fast-dividing cells may support their survival and damp the inflammatory cascade before ulcers form.

Where the evidence stands

Flag text

The mechanism

What is going on, and why this might help

What is going on in the mouth during cancer treatment

The lining of the mouth renews itself rapidly, which is exactly what makes it vulnerable to treatments aimed at fast-dividing cells. Chemotherapy and radiotherapy generate a burst of reactive oxygen species and inflammatory signalling in those cells, which sets off a cascade of cytokine release, tissue breakdown and eventually ulceration. Once ulcers form they are painful, slow to heal and prone to infection, and they can be severe enough to require opioid pain relief or feeding support.

What the light is absorbed by

Cytochrome c oxidase in the mitochondria of the mucosal cells absorbs red light at 632.8 to 660 nm. The model is that photons displace inhibitory nitric oxide from the enzyme, briefly lifting oxygen consumption and ATP production in cells under severe metabolic stress, while the nitric oxide released locally increases blood flow. The accompanying low-level burst of reactive oxygen species acts as a redox signal rather than as damage, shifting transcription factors towards antioxidant defence and resolution of inflammation. The proposed effect is to damp the cascade before ulcers form and, where tissue has broken down, to support re-epithelialisation and reduce local pain signalling.

The biphasic dose response

This is the use where dose is controlled most tightly, and that is not a coincidence. The recommended protocols specify 1 to 6 joules per square centimetre per site, daily through the cancer treatment, with the wavelength, spot size and number of intraoral sites all named. The field's general dose curve, with no effect below a threshold and a decline above the window, is exactly why the guidelines are written with that level of specificity rather than as a general instruction to use red light.

How far the light actually goes

The oral mucosa is a fraction of a millimetre thick and the probe is placed directly against it, so essentially the whole intended dose arrives at the target. There is no skin, fat, bone or hair in the way. That is the single clearest reason this use has the strongest evidence in the field, and the clearest illustration of the general rule: red light performs best where it does not have to travel. Applying light to the outside of the cheeks, or standing in a panel, does not reproduce this, and members having cancer treatment should raise any light exposure with their oncology team before using it.

Explainer illustration

The studies

Every study is laid out the same way: what the researchers wanted to find out, who took part, what they actually did, what they found, why it might work and where the limits are. No jargon, and a link to the original if you want to read it yourself.

Each study is laid out the same way: what the researchers asked, who took part, what they did, what they found, why it might work, and where the limits are. The clinician layer at the end of each one carries the numbers.

Paper 1

Effect of prophylactic low level laser therapy on oral mucositis: a systematic review and meta-analysis

Oberoi et al. · PLoS One · 2014 · Systematic review and meta-analysis of 18 randomised trials, n=1,144

Read the paper

What they asked

Severe mouth ulceration during cancer treatment is one of the most distressing side effects people report, and options to prevent it were limited. Individual trials of light applied inside the mouth had been positive but small. This Canadian-led team asked whether, pooled across all the randomised evidence, preventive light therapy reduces the risk of severe mucositis and severe mouth pain compared with placebo or no light.

Who took part

Eighteen randomised trials covering 1,144 adults and children having cancer treatments known to cause mucositis, principally high-dose chemotherapy before a stem cell transplant and radiotherapy to the head and neck. All were receiving their light preventively, starting before or at the beginning of the cancer treatment rather than once ulcers had already formed.

What they did

The reviewers searched systematically for randomised trials, extracted the rate of severe mucositis, graded on standard clinical scales, and the rate of severe pain. They assessed each trial for risk of bias and pooled the results, examining whether findings held across different cancer treatments and different light settings.

What they found

Preventive light was associated with roughly a 63 per cent reduction in the risk of severe mucositis, a relative risk of about 0.37, and roughly a 74 per cent reduction in severe pain. The direction of effect was consistent across trials. Adverse effects attributable to the light were not a notable feature of the included studies.

What it means

This is the analysis that made the rest of the field take dose seriously. A sizeable, consistent effect on a hard clinical outcome, measured by staff using standard grading scales, is a different order of evidence from a wrinkle score. It is also the clearest demonstration that light does something real to living tissue when the right dose actually arrives at the target.

Limits

Individual trials varied in device, wavelength, dose and how many sites in the mouth were treated, so a single pooled number hides real differences. Blinding is difficult when a light is applied inside the mouth by a clinician. Trial sizes were modest and some were older. Crucially the finding is about prevention, starting before ulcers form, and says much less about treating ulceration that has already developed.

Paper 2

Systematic review of photobiomodulation for the management of oral mucositis in cancer patients and clinical practice guidelines

Zadik et al. · Supportive Care in Cancer · 2019 · MASCC/ISOO systematic review underpinning international guidelines

Read the paper

What they asked

The Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology periodically review every intervention for mucositis. This was their dedicated review of light therapy, and it asked not only whether light works but in which specific cancer treatment settings, and at exactly what device settings, so that oncology teams could be given something they could follow.

Who took part

As a systematic review, its participants are those of the trials it gathered: adults and children having treatments known to cause mucositis. The three settings examined separately were adults having a stem cell transplant after high-dose chemotherapy with or without total body irradiation, adults having head and neck radiotherapy alone, and adults having combined chemotherapy and radiotherapy to the head and neck. Children were considered separately because the dosing and safety data were thinner.

What they did

A multinational panel of oral medicine specialists, oncologists and photobiology researchers searched the literature, graded every study for quality and risk of bias using a standard framework, and judged the strength of evidence for each setting. Rather than treating all light devices as equivalent, they specified wavelength, power density, energy per site, spot size, the number of sites inside the mouth and the schedule used in the supporting trials. Where evidence was inconsistent or settings were not comparable, they declined to recommend.

What they found

The panel concluded that the evidence supports preventive photobiomodulation at specific settings in three populations: adults having a stem cell transplant after high-dose chemotherapy, adults having head and neck radiotherapy alone, and adults having combined chemoradiotherapy. Recommended protocols use 632.8, 650 or 660 nm at roughly 1 to 6 joules per square centimetre per site. For treating established mucositis, and for mucositis from chemotherapy without transplant, the evidence was judged insufficient.

What it means

This is what a mature evidence base looks like in this field, and it is instructive precisely because the recommendations are so narrow. The panel did not conclude that light is good for mouths; it concluded that a named wavelength at a named energy applied to named sites on a named schedule prevents a specific complication in three specific situations. That is the standard the rest of the field has not reached.

Limits

The recommendations cannot be extrapolated. They describe intraoral application by trained staff at controlled doses, not consumer devices and not light applied to the outside of the cheeks. Evidence for treating established ulcers remains weak. Long-term tumour safety data, while reassuring in the reviews available, are still limited, and the panel advised caution where the tumour itself sits in the mouth. Several panel members research or consult in this field.

Paper 3

MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy

Elad et al. · Cancer · 2020 · International clinical practice guideline

Read the paper

What they asked

The 2019 review answered what the evidence showed; this guideline answered what oncology teams should actually do. It asked which interventions for mucositis, across drugs, mouth care protocols, cryotherapy and light therapy, merit a formal recommendation, at what strength, and in which cancer treatment settings.

Who took part

The guideline was produced by an international panel across oral medicine, oncology, nursing and dentistry, working from the systematic reviews of all the evidence available for each intervention. The populations covered are people of all ages receiving chemotherapy, radiotherapy or both, grouped by the kind of cancer treatment they were having rather than by cancer type.

What they did

The panel took the graded evidence from each dedicated systematic review, including the photobiomodulation one, and converted it into formal recommendations, suggestions or statements that no guideline could be made. Each recommendation names the population, the intervention and the specific parameters, and carries an explicit level of evidence.

What they found

Photobiomodulation entered the guideline as a recommended intervention for preventing oral mucositis in adults having a stem cell transplant after high-dose chemotherapy and in adults having radiotherapy to the head and neck, with detailed protocols attached. Two of these recommendations sit at the highest evidence level the guideline uses.

What it means

Formal adoption into international oncology guidance is the highest bar any use of red light has cleared. It is worth stating plainly what that does and does not mean for members: it shows the underlying biology is real and can produce clinically meaningful outcomes when the dose is precisely controlled at a thin, accessible tissue. It does not mean a panel session delivers anything comparable to a shoulder or a knee.

Limits

Guidelines are conservative by design and are tied to the settings that were studied. The recommendations apply to prevention in defined cancer treatment populations, delivered inside the mouth by trained staff. They do not cover treating established mucositis, mucositis from other causes, or any use outside oncology. Guidelines are also periodically revised, and this one reflects the evidence available up to its publication.